Carl Zeiss Meditec AG
XETRA:AFX
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| DE |
|
Carl Zeiss Meditec AG
XETRA:AFX
|
2.4B EUR |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
188.9B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
172B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
138.8B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
131.1B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
114.7B USD |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
59.5B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
46.5B EUR |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
51.7B USD |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
46.7B USD |
Loading...
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
38.2B USD |
Loading...
|
Market Distribution
| Min | -61 459.6% |
| 30th Percentile | 0.7% |
| Median | 4.5% |
| 70th Percentile | 9.8% |
| Max | 94 540% |
Other Profitability Ratios
Carl Zeiss Meditec AG
Glance View
Carl Zeiss Meditec AG stands as a beacon in the realm of medical technology, carving a niche through its innovative solutions in ophthalmology and microsurgery. Rooted in the prestigious legacy of the Zeiss Group, this company seamlessly fuses cutting-edge technology with practical medical applications. Its headquarters in Jena, Germany, serve as the crucible for pioneering research and development endeavors, channeling expertise into products that enhance both diagnostic and surgical capabilities. The heart of its operations revolves around creating technological marvels such as optical coherence tomography (OCT) instruments and surgical microscopes, which bring precision and enhanced clarity to the medical field. Through a well-executed blend of R&D and strategic acquisitions, Carl Zeiss Meditec consistently remains at the forefront of medical innovation, ensuring it meets the ever-evolving needs of the healthcare sector. Financially, the company thrives by selling its sophisticated medical devices directly to healthcare professionals, hospitals, and clinics worldwide. Rather than merely creating instruments, Carl Zeiss Meditec's business model is deeply entwined with providing comprehensive workflow solutions and service support, ensuring that medical practitioners extract maximum utility from their investments. By offering not just products but also extensive after-sales service and maintenance, the company builds sustained relationships with its clients, fostering a cycle of trust and repeat business. In addition, its engagement in training and support services enhances user competencies, ensuring the seamless integration of its technology into everyday medical practice and underscoring its commitment to elevating healthcare standards globally. Through this multifaceted approach, Carl Zeiss Meditec solidifies its position as an indispensable ally in the medical community, both as a supplier of state-of-the-art equipment and as a provider of essential healthcare solutions.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Carl Zeiss Meditec AG is 10%, which is below its 3-year median of 12.8%.
Over the last 3 years, Carl Zeiss Meditec AG’s Operating Margin has decreased from 20.9% to 10%. During this period, it reached a low of 8.5% on Jun 30, 2025 and a high of 20.9% on Sep 30, 2022.